Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma

This article reviews clinical case of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer and the usage of osimertinib for its treatment. Targeted drugs, EGFR tyrosine kinase inhibitors were approved for the treatment of non-small cell lung cancer more than 15 years...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Svetlana V. Odintsova, Mariia A. Sviridenko, Antonina O. Cheremnykh, Elena A. Filippova, Magaripa A. Urtenova, Sergei V. Orlov
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitors osimertinib epidermal growth factor receptor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/35b34aa048204aa58f62d993ec1f67bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:35b34aa048204aa58f62d993ec1f67bc
record_format	dspace
spelling	oai:doaj.org-article:35b34aa048204aa58f62d993ec1f67bc2021-11-30T17:03:34ZClinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma1815-14341815-144210.26442/18151434.2020.2.200153https://doaj.org/article/35b34aa048204aa58f62d993ec1f67bc2020-07-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34962/23379https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442This article reviews clinical case of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer and the usage of osimertinib for its treatment. Targeted drugs, EGFR tyrosine kinase inhibitors were approved for the treatment of non-small cell lung cancer more than 15 years ago*. Updated results of the large multicenter randomized FLAURA trial showed that osimertinib, a third-generation irreversible selective epidermal growth factor receptor tyrosine kinase inhibitor, was more effective than first-generation EGFR tyrosine kinase inhibitors, not only in terms of progression-free survival, but in terms of duration of response and overall survival. Furthermore, statistically and clinically significant benefit is achieved without deterioration of tolerance and quality of life. This article presents a clinical case of a woman who has taken part in this clinical trial. In light of the fact that this patient has been one of the first to receive this therapy in Russia, this experience appears to be interesting, because it allows assess the long-term results of the therapy: the achieved response duration is more than 50 months with good tolerance of therapy.Svetlana V. OdintsovaMariia A. SviridenkoAntonina O. CheremnykhElena A. FilippovaMagaripa A. UrtenovaSergei V. OrlovIP Habib O.N.articlenon-small cell lung cancerepidermal growth factor receptor tyrosine kinase inhibitorsosimertinibepidermal growth factor receptorNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 108-111 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitors osimertinib epidermal growth factor receptor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitors osimertinib epidermal growth factor receptor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Svetlana V. Odintsova Mariia A. Sviridenko Antonina O. Cheremnykh Elena A. Filippova Magaripa A. Urtenova Sergei V. Orlov Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
description	This article reviews clinical case of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer and the usage of osimertinib for its treatment. Targeted drugs, EGFR tyrosine kinase inhibitors were approved for the treatment of non-small cell lung cancer more than 15 years ago*. Updated results of the large multicenter randomized FLAURA trial showed that osimertinib, a third-generation irreversible selective epidermal growth factor receptor tyrosine kinase inhibitor, was more effective than first-generation EGFR tyrosine kinase inhibitors, not only in terms of progression-free survival, but in terms of duration of response and overall survival. Furthermore, statistically and clinically significant benefit is achieved without deterioration of tolerance and quality of life. This article presents a clinical case of a woman who has taken part in this clinical trial. In light of the fact that this patient has been one of the first to receive this therapy in Russia, this experience appears to be interesting, because it allows assess the long-term results of the therapy: the achieved response duration is more than 50 months with good tolerance of therapy.
format	article
author	Svetlana V. Odintsova Mariia A. Sviridenko Antonina O. Cheremnykh Elena A. Filippova Magaripa A. Urtenova Sergei V. Orlov
author_facet	Svetlana V. Odintsova Mariia A. Sviridenko Antonina O. Cheremnykh Elena A. Filippova Magaripa A. Urtenova Sergei V. Orlov
author_sort	Svetlana V. Odintsova
title	Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
title_short	Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
title_full	Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
title_fullStr	Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
title_full_unstemmed	Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
title_sort	clinical case of long-term use of osimertinib in the treatment of egfr mutation-positive lung adenocarcinoma
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/35b34aa048204aa58f62d993ec1f67bc
work_keys_str_mv	AT svetlanavodintsova clinicalcaseoflongtermuseofosimertinibinthetreatmentofegfrmutationpositivelungadenocarcinoma AT mariiaasviridenko clinicalcaseoflongtermuseofosimertinibinthetreatmentofegfrmutationpositivelungadenocarcinoma AT antoninaocheremnykh clinicalcaseoflongtermuseofosimertinibinthetreatmentofegfrmutationpositivelungadenocarcinoma AT elenaafilippova clinicalcaseoflongtermuseofosimertinibinthetreatmentofegfrmutationpositivelungadenocarcinoma AT magaripaaurtenova clinicalcaseoflongtermuseofosimertinibinthetreatmentofegfrmutationpositivelungadenocarcinoma AT sergeivorlov clinicalcaseoflongtermuseofosimertinibinthetreatmentofegfrmutationpositivelungadenocarcinoma
_version_	1718406371981918208

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma

Ejemplares similares